Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

L. M. Demeter, R. W. Shafer, P. M. Meehan, J. Holden-Wiltse, Margaret A Fischl, W. W. Freimuth, M. F. Para, R. C. Reichman

Research output: Contribution to journalArticle

75 Scopus citations


The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

Original languageEnglish
Pages (from-to)794-797
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Issue number3
StatePublished - Mar 1 2000


ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this